Home-based Spinal Cord Stimulation for Hand & Arm Function in MS
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- University of Washington
- Study ID
- NCT07673354
- Status
- Enrolling By Invitation
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Spinal Cord Stimulation + Hand/arm Exercises — COMBINATION_PRODUCTA two-channel transcutaneous spinal cord stimulator (SCONE, SpineX, Inc.) will deliver non-invasive electrical stimulation during hand/arm exercise sessions. For each session, two self-adhesive hydrogel electrodes will be positioned along the midline of the C3-C4 and C6-C7 spinous processes over the skin. The electrical current employed for the transcutaneous spinal cord stimulation is biphasic, featuring a 1-millisecond pulse width, a base frequency of 30 Hz, and an overlapping frequency of 10 kHz. Stimulation intensity will be individualized for each participant, up to a maximum of 120 milliamperes (mA). The hand/arm exercise program is comprised of intensive, progressive, functional task practice following a standardized protocol. The protocol consists of repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance.
Study Details
This is a pilot study designed to test the feasibility of in-home, non-invasive (transcutaneous, applied by surface electrodes over the skin) electrical spinal cord stimulation combined with exercises for restoring upper extremity sensorimotor function in adults with multiple sclerosis. Participants with multiple sclerosis and impaired upper extremity function will complete 8-weeks of hand/arm exercises combined with spinal cord stimulation performed at home with the help of a partner. The investigators hypothesize that: 1. in-home transcutaneous spinal cord stimulation combined with hand/arm exercises will be feasible and acceptable by participants 2. in-home transcutaneous spinal cord stimulation combined with hand/arm exercises will lead to improvements in upper extremity function after 8-weeks 3. in-home transcutaneous spinal cord stimulation combined with therapy will lead to improvements in symptoms related to quality of life (pain, spasticity, and bladder symptoms)
Key Dates
- Start date
- Jul 16, 2026
- Status verified
- Jun 2026
- Primary completion
- Mar 1, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 2 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Home Exercise + Spinal Cord StimulationThe 8-week intervention will consist of approximately 1-hour sessions, 3-4x times per week. These sessions will occur in the participant's home, during which hand/arm exercises and transcutaneous spinal cord stimulation (tSCS) will be performed. A caregiver or partner will assist with electrode placement and tSCS administration. Exercises are similar to what would be prescribed by an occupational therapist for an outpatient home exercise program, and include: repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance.
Primary Outcome Measure
Retention rate [ Time Frame: 8 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Washington | Seattle | Washington | 98195 | - |
Find similar trials in Seattle, WA
Related Studies
- Complementary and Alternative Care in Multiple SclerosisRecruiting · Bastyr University · Kenmore, Washington
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)Recruiting · TG Therapeutics, Inc. · Birmingham, Alabama
- Confirmatory Trial for Alleviating Fatigue in Multiple SclerosisRecruiting · Accelerated Cure Project for Multiple Sclerosis · Washington D.C., District of Columbia